CSIMarket Company Name, Ticker, Suppliers, else..
 
  (INM)
Other Ticker:  
 
 
Price: $0.2573 $0.01 2.266%
Day's High: $0.2579 Week Perf: -11.28 %
Day's Low: $ 0.25 30 Day Perf: 83.26 %
Volume (M): 215 52 Wk High: $ 2.08
Volume (M$): $ 55 52 Wk Avg: $0.36
Open: $0.25 52 Wk Low: $0.12



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 8
 Employees -
 Revenues (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0


InMed Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the research and development of cannabinoid-based therapies. The company utilizes its proprietary bioinformatics platform, called INM-101, to identify potential drug targets and develop novel therapies for specific diseases and conditions. InMed's goal is to leverage the therapeutic benefits of cannabinoids to address unmet medical needs in areas such as dermatology, ophthalmology, and pain management. The company is based in Vancouver, British Columbia, Canada, and is listed on the Toronto Stock Exchange.


   Company Address: Suite 310 - 815 W. Hastings Street B.C 0
   Company Phone Number: 669-7207   Stock Exchange / Ticker: NASDAQ INM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Alzamend Neuro Inc

Alzamend Neuro Inc announced operating deficit in the first quarter of 2024

The shareholders haven't hoped for some modifications at the revenue throughout the the earnings cycle of fiscal May to July 31 2024 at the Alzamend Neuro Inc . However, they observe the Major Pharmaceutical Preparations company's operating deficit that was at $-0.962405 million, in the same period.

Avid Bioservices Inc

An exceptional quarter for CDMO in the May to July 31 2024 period

For the most recent fiscal period CDMO Losses have extended of $-0.09 per share compare to $-0.03 a year prior and Income per Share improved from $-1.94 per share from the prior quarter. The Revenue advanced by 8.283 % to $40.17 million from $37.10 million in the corresponding quarter a year prior and sequentially Revenue deteriorated by -7.648 % from $43.50 million.

Catalent Inc

Catalent Inc Soars with an Astonishing 23.3% Revenue Surge in Q4 2024: What?s Behind This Impressive Growth?

Surge in Revenue could not lift Catalent Inc s' profitability, in the fourth quarter of 2024 financial report earnings per share remained unscathed at $0.13 per share, revenue jumped by 23.318 % to $1.30 billion from the corresponding reporting season a year ago.

Cingulate Inc

The Major Pharmaceutical Preparations company released operating deficit of $-6.797151 million, in the fourth quarter of 2023 financial report

The Major Pharmaceutical Preparations sector observers start to digest the fourth quarter of 2023 numbers. Now they follow operating deficit of $-6.797151 million, from the CING, as it has not cited any revenue yet, for the respective October to December 31 2023 financial reporting period.

Phibro Animal Health Corporation

Income Tumbles by -93.47 % at the Phibro Animal Health Corporation over the fourth quarter of 2024 earnings season

PAHC announced income per share of $0.02 and Revenue of $262.60 million in its financial interval ending June 30 2024, Phibro Animal Health Corporations' income fell sharply $0.02 per share, versus $0.28 eps, earned in the same interval a preceding year, although the Major Pharmaceutical Preparations company saw its Revenue rise by 7.765 % in the same period. PAHCs' business rose at higher rate in contrast to the the revenue at nearly all of the Major Pharmaceutical Preparations sector peers, in the fourth quarter of 2024 the two third entities in Major Pharmaceutical Preparations industries saw an average business advance of 5.01% relative to the same period a year ago.







's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com